Skip to main content
. 2015 May 8;126(2):233–241. doi: 10.1182/blood-2015-03-633537

Figure 2.

Figure 2

OS and CI of disease progression of patients with MDS with ring sideroblasts classified according to SF3B1 mutation status. (A-B) Respectively, OS and CI of disease progression of the whole cohort of MDS with ring sideroblasts according to SF3B1 mutation status (total number of patients = 243; SF3B1 mutated = 151, SF3B1 unmutated = 92) (P values from multivariable analyses, OS: P = .003; CI of disease progression: P = .018). (C-D) Respectively, OS and CI of disease progression of patients with MDS classified into sideroblastic categories (ie, RARS and RCMD-RS) (total number of patients = 159; SF3B1 mutated = 129, SF3B1 unmutated = 30) (P values from multivariable analyses, OS: P = .007; CI of disease progression: P = .026).